This work investigates the systemic nature of corporate crime within the global pharmaceutical industry and the regulatory failures that allow such misconduct to persist. John Braithwaite, a prominent criminologist, utilizes extensive empirical research and case studies to analyze how pharmaceutical corporations prioritize profit over public safety. The book argues that the industry's structure and the limitations of current regulatory frameworks create an environment where illegal practices are often treated as a cost of doing business rather than a criminal deviation. By examining the intersection of corporate power and government oversight, the author provides a critical framework for understanding the mechanisms of white-collar crime in the medical sector.

Experts in criminology and public health frequently cite this text as a foundational analysis of corporate malfeasance in the pharmaceutical sector. Readers often note the academic density of the prose, which provides a rigorous examination of institutional behavior and regulatory policy.